#novo nordisk

诺和诺德正同时应对两起离职事件，包括 GLP-1 先驱 Lotte Bjerre Knudsen 的退休，以及一位肥胖领域领导者转投勃林格殷格翰。

Novo Nordisk and Hims & Hers have ended their legal battle with a partnership that could reshape the booming compounded GLP-1 drug market and limit cheaper alternatives.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.